Share on StockTwits

Thoratec (NASDAQ:THOR) has been given a consensus recommendation of “Hold” by the nineteen ratings firms that are covering the stock, American Banking and Market News reports. Ten analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $32.64.

A number of research firms have recently commented on THOR. Analysts at Piper Jaffray downgraded shares of Thoratec from an “overweight” rating to a “neutral” rating in a research note on Monday, August 25th. They now have a $27.00 price target on the stock, down previously from $40.00. Separately, analysts at WallachBeth Capital cut their price target on shares of Thoratec from $38.00 to $28.00 in a research note on Wednesday, August 20th. They now have a “hold” rating on the stock. Finally, analysts at Northland Securities downgraded shares of Thoratec from an “outperform” rating to a “market perform” rating in a research note on Monday, August 11th. They now have a $26.00 price target on the stock, down previously from $46.00.

Thoratec (NASDAQ:THOR) opened at 25.00 on Thursday. Thoratec has a one year low of $22.50 and a one year high of $43.58. The stock’s 50-day moving average is $28.55 and its 200-day moving average is $32.76. The company has a market cap of $1.407 billion and a P/E ratio of 21.16.

Thoratec (NASDAQ:THOR) last announced its earnings results on Wednesday, August 6th. The company reported $0.43 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.43. The company had revenue of $118.10 million for the quarter, compared to the consensus estimate of $128.30 million. During the same quarter last year, the company posted $0.52 earnings per share. Thoratec’s revenue was down 9.5% compared to the same quarter last year. On average, analysts predict that Thoratec will post $1.34 earnings per share for the current fiscal year.

Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.

Receive News & Ratings for Thoratec Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thoratec Co and related companies with Analyst Ratings Network's FREE daily email newsletter.